Company intelligence / Profile preview

Eclipse Life Sciences

Research Triangle Park, North Carolina, United Statesotc.duke.edu ↗

Ownership: Private
Development stage: Preclinical

Overview

Eclipse Life Sciences is currently conducting the BETTIS-1 Phase 2 clinical trial for EC-104, a novel intravitreal corticosteroid implant with 6-month durable drug release for treating diabetic macular edema. The first patient was enrolled and dosed in August 2024. The trial is designed as a randomized, controlled, double-masked study comparing two doses of EC-104 to Ozurdex in DME patients with prior suboptimal response to anti-VEGF therapy[2][5][8].

Therapeutic areas: EndocrinologyOphthalmology
Modalities: Small moleculescorticosteroid implantsintravitreal drugs
Industry: Biotech

Drug pipeline

5 assets

EC-104

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Eclipse Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eclipse Life Sciences.

Explore the full profile